Atypical hemolytic uremic syndrome : when the environment and mutations affect organ systems. A case report with review of literature by Abu Ghanimeh, Mouhanna et al.
Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect 
Organ Systems. A Case Report with Review of Literature 
 
Mouhanna Abu Ghanimeh
1
, Omar Abughanimeh
1
, Ayman Qasrawi
1
, Abdulraheem Qasem
2
 
 
1
Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO 
2
Shawnee Mission Medical Center, Shawnee Mission, KS 
 
Correspondence: Mouhanna Abu Ghanimeh (abughanimehm@umkc.edu) 
 
Received February 1, 2017; accepted March 2, 2017 
 
 
Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) with 
a genetic predisposition. Like other TMAs, it presents clinically with thrombocytopenia and 
microangiopathic hemolytic anemia, which is accompanied by disruption of at least one organ 
system. In general, it is important to distinguish aHUS from other TMAs because of the different 
prognosis and treatment options. We present a case of a 42-year-old female who presented with 
abdominal pain, nausea and vomiting. She had hemolytic anemia, thrombocytopenia and acute 
kidney injury suggestive of TMA. She was started on hemodialysis and plasma exchange and 
had an extensive workup including ADAMTS-13 (a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13), which was normal, and complement factor 
mutations, which showed a complement factor H-related protein mutation. The diagnosis of 
aHUS was confirmed; plasma exchange was stopped; and she was started on eculizumab, which 
she tolerated well. However, she was diagnosed with end-stage renal disease and will need long-
term renal replacement therapy. 
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Introduction 
 
Thrombotic microangiopathies (TMAs) are a group of disorders characterized by a tendency to 
develop endothelial cell damage and vascular thrombi resulting in thrombocytopenia and 
hemolysis (1). Additionally, they are accompanied by disruption of at least 1 organ system (2,3). 
Atypical hemolytic uremic syndrome (aHUS) is a chronic genetic disorder associated with 
defective complement control (3-6). Even though a mutation or a genetic predisposition is 
present at birth, the presentation of aHUS can occur at any age. Environmental events that hyper-
activate the alternative complement pathway may be required to cause the overt signs and 
symptoms (4,7,8). It is important to distinguish aHUS from other TMAs, especially thrombotic 
thrombocytopenic purpura (TTP), as the treatment and prognosis differ remarkably (8,9). 
Patients with aHUS are less likely to respond to plasma exchange, and the outcome is poor in 
those patients treated with plasma exchange alone (2,9). Eculizumab is a recombinant, 
humanized, monoclonal antibody that binds human C5 and has been described in the treatment 
of aHUS (9,10).  
 
 Case presentation 
 
A 42-year-old female with a past medical history of benign essential hypertension and 
depression presented to our institution with lower abdominal pain, nausea, and vomiting. She 
recalled eating at a fast-food restaurant two weeks prior to the onset of symptoms. Her initial 
laboratory workup was as follows: white cell count 5,800/cmm (normal 4,000-11,000/cmm), 
hemoglobin 5.8 g/dL (normal 12-16 g/dL), platelet count 73,000/cmm (normal 150,000-
450,000), reticulocyte count 6.2 % (normal 0.5-1.5%), sodium 124 mmol/L (normal 136-144 
mmol/L), chloride 88 mmol/L (normal 95-105 mmol/L), potassium 6.1 mmol/L (normal 3.6-5.1 
mmol/L), bicarbonate 7 mmol/L (normal 20-24 mmol/L), blood urea nitrogen (BUN) 98 mg/dL 
(normal 8-14 mg/dL), creatinine 15.12 mg/dL (normal 0.9-1.2 mg/dL), international normalized 
ratio (INR) 1, lactate dehydrogenase (LDH) 1265 units/L (normal 30-200 units/L), haptoglobin 
<10 mg/dl (41-165 mg/dl) and lipase 140 units/L (normal 13-60 units/L). Her blood film is 
shown in Figure 1. Given her acute kidney injury and electrolyte abnormalities, she was started 
on fluid hydration, and two units of packed red blood cells (PRBCs) were transfused. She was 
admitted to the intensive care unit for close observation.  
 
 
 
 
Figure 1. The peripheral blood smear on presentation showed evidence of microangiopathic hemolytic anemia with 
multiple schistocytes.  
 
   The nephrology team suspected nonsteroidal anti-inflammatory drug-induced nephropathy or 
HUS. The patient’s urine eosinophil test was negative. On day 3 of the patient’s hospitalization, 
the nephrology team recommended the insertion of a dialysis catheter to start hemodialysis (HD) 
due to uremia, anuria and electrolyte abnormalities. They also recommended performing renal 
biopsy in case the patient did not improve with HD. 
   The hematology team thought it was most likely HUS; however, TTP could not be excluded at 
that time. The patient was started on plasma exchange with daily follow-up on platelet count, 
hemoglobin, reticulocyte count, lactate dehydrogenase (LDH), haptoglobin, and bilirubin. The 
goal of plasma exchange was set to keep the platelet count > 150,000/cmm and the LDH < 300 
units/L. 
   The Shiga toxin test was negative. A renal biopsy was performed on day 6 of the 
hospitalization and showed both an acute and subacute thrombotic microangiopathy with 60% 
interstitial fibrosis and tubular atrophy. Eventually, the ADAMTS-13 test (a disintegrin and 
metalloproteinase with a thrombospondin type 1 motif, member 13) showed 76% activity, which 
excluded primary TTP. At this point, the hematology team suspected aHUS. The plan was to 
continue plasma exchange until the diagnosis of aHUS could be confirmed.  
   C3 complement level and complement factor H mutation were ordered. The C3 level was near 
normal, but it was also inconclusive because mutations occur in only approximately 50% of 
cases. Once the patient’s hemolytic parameters started to improve and stabilize (Figure 2), she 
was discharged on hospital day 21, and the plan was to continue with HD and plasma exchange 
three times weekly as an outpatient.  
 
 
 
 
Figure 2. The trend of the patient’s LDH and reticulocyte count during the hospital stay. Notably, the patient was 
discharged on day 21 of hospitalization.  
 
 
   The patient’s complement factor H mutation testing came back after 6 weeks. The results 
showed complement factor H-related protein (CFHRs) mutations of unknown significance. 
Plasma exchange was stopped, and the patient was started on eculizumab. She received the 
meningococcal conjugate vaccine and ciprofloxacin prophylaxis prior to initiation. She is 
currently being followed in the hematology clinic and is tolerating the eculizumab treatment 
well. Her kidney function did not completely improve, and she was diagnosed with end-stage 
renal disease (ESRD). The patient continues to need HD and may need an arteriovenous fistula 
in the future. 
 
Discussion 
 
TMAs syndromes are a group of very diverse diseases that share common clinical and pathologic 
features. These diseases are characterized by a tendency to develop endothelial cell damage and 
vascular thrombi (1). Clinically, they present with thrombocytopenia, microangiopathic 
hemolytic anemia and at least one organ system disruption (1-3). Characteristic laboratorial 
findings include: evidence of intravascular hemolysis with low hemoglobin, high reticulocyte 
count, low haptoglobin, an elevated LDH, schistocytes on a peripheral blood smear and a 
negative direct Coombs assay. TMAs may be primary or secondary. The primary TMAs can be 
hereditary or acquired. The primary hereditary form involves hereditary mutations in the 
ADAMSTS-13, mutations in complement genes (CFH, CFI, CFB, C3, CD46, and other 
complement genes); mutations in MMACHC (which cause metabolism-mediated TMA); and 
mutations in the DGKE, PLG and THBD genes (which cause coagulation-mediated TMA). The 
acquired primary TMA syndromes include autoimmune ADAMSTS-13 deficiency (TTP), Shiga 
toxin-mediated TMA, drug-mediated TMA and complement-mediated TMA. TMAs can be 
secondary to a manifestation of systemic diseases such as systemic infection, disseminated 
intravascular coagulation (DIC), malignant hypertension, preeclampsia/eclampsia, HELLP 
(hemolysis, elevated liver enzymes, and low platelets) syndrome, and catastrophic anti-
phospholipid syndrome (3). 
   Most HUSs are triggered by a Shiga-like toxin-producing Escherichia coli. aHUS is less 
common. It is a genetic disorder associated with a defective complement control, mainly in the 
alternative pathway (3-6). Recent data show that 50% of aHUS cases are associated with 
mutations in genes that encode complement regulatory proteins (5,6).  
   The presentation of aHUS can occur at any age. This is usually the result of interaction of the 
genetic mutations that presents at birth with other environmental events that hyper-activate the 
complement pathway (4,7,8).  
   It is important to distinguish aHUS from TTP (8,9). This can be done based on ADAMTS-13 
activity. TTP is associated with less than 5% activity because of the presence of an anti-
ADAMTS-13 inhibitor, usually an IgG autoantibody (2,8,9). Normally, ADAMTS-13 activity is 
67% to 100%. The autoantibodies to ADAMTS-13 are usually absent, but, low titers can be 
found in approximately 4% of the healthy population (7). Shiga toxin and ADAMTS-13 activity 
are important in the evaluation of any TMA, especially the one that is accompanied by diarrhea 
(7,8). 
   Usually, the response to plasma exchange is different between TTP and aHUS (8,9). TTP 
responds very well to plasma exchange. Its mortality declines from more than 90% to less than 
10% with plasma exchange, but the outcome is poor in aHUS patients treated with plasma 
exchange alone (2). Consequently, plasma exchange should be started as soon as possible for any 
new patient presenting TMA, even before the results of the specific laboratory tests come back. 
The response to plasma exchange in addition to other laboratory tests can be used to distinguish 
among main different types of TMAs (2). 
   Eculizumab is a recombinant, humanized, monoclonal immunoglobulin G antibody that is used 
in the treatment of aHUS (9,10). Eculizumab inhibit the formation of the membrane attack 
complex by binding human complement 5 and inhibiting the activation of terminal complement 
components (9).  
   The prognosis in aHUS is not that favorable (11). Up to 25% may die during the acute phase in 
the absence of appropriate management (11). Approximately, 50% of aHUS patients may 
progress to ESRD within a year and recurrence occurs in 60-100% of patients even after kidney 
transplantation (12). 
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